InsiderTrades.com logo
Jennifer Lew net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Jennifer Lew Biography and Net Worth

CFO of Annexon
Ms. Lew joined Annexon Biosciences as Chief Financial Officer in June 2019. She previously served as Chief Financial Officer for Aduro Biotech, Inc. While at Aduro, Ms. Lew played a leadership role in the company’s preparation and execution of its initial public offering and provided financial and strategic oversight in areas of fundraising, investor relations, strategic planning and board governance. Prior to Aduro, Ms. Lew held various roles at Dynavax Technologies Corporation from 2004 to October 2013, most recently as Vice President of Finance and Principal Accounting Officer, where she was responsible for finance and accounting operations. Before joining Dynavax, Ms. Lew held positions as Assistant Controller and Director of Finance at QRS Corporation, a publicly-held technology company, from 2000 to 2004. Ms. Lew began her career in the audit practice at Ernst & Young from 1994 to 1999. She earned a B.A. in Economics/Accounting and Government from Claremont McKenna College and is a Certified Public Accountant (inactive status).

What is Jennifer Lew's net worth?

The estimated net worth of Jennifer Lew is at least $174,982.50 as of February 18th, 2025. Ms. Lew owns 77,770 shares of Annexon stock worth more than $174,983 as of March 29th. This net worth evaluation does not reflect any other assets that Ms. Lew may own. Additionally, Ms. Lew receives a salary of $624,200.00 as CFO at Annexon. Learn More about Jennifer Lew's net worth.

How old is Jennifer Lew?

Ms. Lew is currently 51 years old. There are 5 older executives and no younger executives at Annexon. The oldest executive at Annexon is Dr. Ted Yednock Ph.D., Executive VP, Chief Innovation Officer & Chairman of the Scientific Advisory Board, who is 66 years old. Learn More on Jennifer Lew's age.

What is Jennifer Lew's salary?

As the CFO of Annexon, Inc., Ms. Lew earns $624,200.00 per year. There are 3 executives that earn more than Ms. Lew. The highest earning executive at Annexon is Mr. Douglas Love Esq., J.D., CEO, President & Director, who commands a salary of $980,120.00 per year. Learn More on Jennifer Lew's salary.

How do I contact Jennifer Lew?

The corporate mailing address for Ms. Lew and other Annexon executives is , , . Annexon can also be reached via phone at 650-822-5500 and via email at swheeler@wheelhouselsa.com. Learn More on Jennifer Lew's contact information.

Has Jennifer Lew been buying or selling shares of Annexon?

Over the course of the past ninety days, Jennifer Lew has sold $25,505.32 in Annexon stock. Most recently, Jennifer Lew sold 6,912 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $2.92, for a transaction totalling $20,183.04. Following the completion of the sale, the chief financial officer now directly owns 77,770 shares of the company's stock, valued at $227,088.40. Learn More on Jennifer Lew's trading history.

Who are Annexon's active insiders?

Annexon's insider roster includes Sanjay Keswani (EVP), Jennifer Lew (CFO), Douglas Love (CEO), and Ted Yednock (EVP). Learn More on Annexon's active insiders.

Are insiders buying or selling shares of Annexon?

During the last twelve months, Annexon insiders bought shares 5 times. They purchased a total of 16,000 shares worth more than $89,984.00. During the last twelve months, insiders at the sold shares 12 times. They sold a total of 48,976 shares worth more than $224,444.81. The most recent insider tranaction occured on February, 18th when insider Jamie Dananberg sold 5,521 shares worth more than $16,342.16. Insiders at Annexon own 12.7% of the company. Learn More about insider trades at Annexon.

Information on this page was last updated on 2/18/2025.

Jennifer Lew Insider Trading History at Annexon

See Full Table

Jennifer Lew Buying and Selling Activity at Annexon

This chart shows Jennifer Lew's buying and selling at Annexon by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$26ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$20k-$10k$0$10k$20kTotal Insider BuyingTotal Insider Selling

Annexon Company Overview

Annexon logo
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Read More

Today's Range

Now: $2.25
Low: $2.21
High: $2.31

50 Day Range

MA: $3.05
Low: $2.24
High: $4.24

2 Week Range

Now: $2.25
Low: $2.18
High: $7.85

Volume

1,086,710 shs

Average Volume

1,758,707 shs

Market Capitalization

$246.85 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.14